Summary The p53 tumour-suppressor gene is found altered in the majority of colorectal cancers. Lesions include allelic loss, mutation of the gene and overexpression of the p53 protein. All of these lesions have been analysed for prognostic significance, and whereas both mutation and allelic loss have been shown to be reasonably useful markers of prognosis, the utility of overexpression of the p53 protein is more ambiguous.
The p53 tumour-suppressor gene is the most commonly altered gene in solid human neoplasia (Hollstein et al., 1991; Levine et al., 1991) . The p53 gene was first identified by its ability to complex with SV40 large T antigen (Lane and Crawford, 1979) and the adenovirus type 5 EIB 58KD protein (Sarnow et al., 1982) . Localisation of the gene showed that the p53 gene resides at chromosomal location Chl7pl3.1 (Isobe et al., 1986; McBride et al., 1986) , a site that is frequently found to have undergone allelic deletion in many cancers (Baker et al., 1989; Takahashi et al., 1989; Mulligan et al., 1990) . The remaining allele of the p53 gene is commonly found to be mutated (Baker et al., 1989 Takahashi et al., 1989; Nigro et al., 1989) . The wild-type (non-mutated) protein has the ability to reduce or eliminate the tumorigenic potential of a cell line (Chen et al., 1990) . The mutated protein has lost this ability, and shows oncogenic activity (Hinds et al., 1989 (Hinds et al., , 1990 . Used alone in transformation assays the mutated protein is able to immortalise primary fibroblasts (Jenkins et al., 1984; Rovinski and Benchimol, 1988) , and when used in conjunction with activated ras, mutated p53 can fully transform primary fibroblasts (Parada et al., 1984; Eliyahu et al., 1989; Hinds et al., 1990) .
Wild-type p53 has a short half-life of about 15 min (Oren et al., 1981) , and is turned over rapidly by an ATP-dependent degradation pathway (Gronostajski et al., 1984) . Mutations within the p53 gene often lead to proteins with a greater stability, with half-lives of up to 20 h in some cases (Oren et al., 1981; Reich et al., 1983) . The mutant protein accumulates within the malignant cell and can be readily detected by immunohistochemistry, as opposed to normal cells, in which the protein is essentially undetectable by normal methods (Rodriguez et al., 1990) . Mutations of the p53 gene often lead to conformational changes within the p53 protein with the resultant accessibility of epitopes normally unavailable for antibody recognition (Cook and Milner, 1990) .
Allelic loss of the p53 gene has been shown to occur in up to 70% of colorectal cancers (Kern et al., 1989; Khine et al., 1994) , and is associated with tumour progression, particularly the presence of distant organ metastasis (Khine et al., 1994) . In short-term studies, allele loss of p53 does not provide prognostic information (O'Connell et al., 1992; Campo et al., 1994; Khine et al., 1995) , but in studies with longer follow-up periods, allelic loss of one copy of the p53 gene is a significant indicator of a poorer patient prognosis (Kern et al., 1989; Laurent-Puig et al., 1992) . Point mutation of the p53 gene occurs in approximately 50% of colorectal carcinomas (Hollstein et al., 1991; Goh et al., 1994) , and is also associated with tumour progression (Goh et al., 1994 ) and a poorer patient prognosis (Hamelin et al., 1994; Goh et al., 1995) , although this is not found by some authors (Dix et al., 1994a, Table I ).
Over-expression of the p53 protein has been reported to occur in 24-72% of colorectal cancers, with a large part of the variation residing in the specificities of the antibodies use in these studies, and to a lesser extent to what the authors define as overexpression (Rodriguez et al., 1990; Scott et al., 1991; Starzynska et al., 1992; Remvikos et al., 1992; Yamaguchi et al., 1992 Yamaguchi et al., , 1993 Bell et al., 1993; Sun et al., 1992; Bosari et al., 1994; Nathanson et al., 1994; Dix et al., 1994b; Mulder et al., 1995) . At least 11 studies (see Table II) have examined p53 over-expression with respect to patient survival in colorectal cancer patients (Scott et al., 1991; Remvikos et al., 1992; Starzynska et al., 1992; Sun et al., 1992; Yamaguchi et al., 1992 Yamaguchi et al., , 1993 Bell et al., 1993; Bosari et al., 1994; Dix et al., 1994a; Nathanson et al., 1994; Mulder et al., 1995) . Six of these studies found that overexpression of the p53 gene is significantly associated with a poorer patient prognosis in univariate analysis (Remvikos et al., 1992; Starzynska et al., 1992; Yamaguchi et al., 1992 Yamaguchi et al., , 1993 Bosari et al., 1994; Dix et al., 1994a) . The remaining five studies do not detect a demonstrable relationship between patient survival and nuclear p53 overexpression (Scott et al., 1991; Sun et al., 1992; Bell et al., 1993; Nathanson et al., 1994; Mulder et al., 1995) . Two groups have noted a poorer patient prognosis associated with the detection of immunoreactive p53 in the cytoplasm of colorectal adenocarcinoma cells (Sun et al., 1992; Bosari et al., 1994) although the significance of this remains unclear. In this study we have examined p53 overexpression and patient survival in a cohort in which information on p53 mutation status is also examined. Mutation analysis Analysis of colorectal carcinomas was undertaken exactly as described in detail elsewhere (Smith et al., 1994a, b) and cohort contains samples previously described (Smith et al., 1994a, b; Goh et al., 1994 Goh et al., , 1995 . Briefly, a first-strand cDNA copy was made from total RNA using random hexamers. This was used as a template in a polymerase chain reaction to amplify a 644 bp cDNA fragment of p53, which contains the region known to contain 98% of all point mutations of the p53 gene (Hollstein et al., 1991) . This fragment was digested with the restriction endonuclease MspI, fragments dephosphorylated with calf intestinal alkaline phosphatase and labelled with 32P-y-ATP. The digestion products were then analysed on a 6% polyacrylamide non-denaturing gel. Samples were analysed by duplicate reverse transcriptase polymerase chain reaction single-stranded conformation polymorphism (RT-PCR-SSCP), and selected cases confirmed by DNA sequencing (Banks et al., 1989) and PAb 240 were used to analyse each specimen, as evidence has shown that not all antibodies have comparable reactivity (Cook and Milner, 1990 (Figure 1 ). As has been reported by other workers staining was predominantely nuclear (Rodriguez et al., 1990; Scott et al., 1991; Remvikos et al., 1992; Starzynska et al., 1992; Sun et al., 1992; Yamaguchi et al., 1992; Bell et al., 1993; Bosari et al., 1994) , although some cases of cytoplasmic staining were noted. The distribution of staining was variable with some tumours showing extensive staining over almost the whole section Table IV) .
Mutation of the p53 gene was detected by single-stranded conformational polymorphisms (Orita et al., 1989a, b) using the modification of Sakai and Tsuchida (1992) as described in detail elsewhere (Smith et al., 1994a, b) . Mutation of the p53 gene was detected in 51% of the tumours (Figure 2) . Point mutation of the p53 gene was weakly associated with the presence of detectable levels of immunoreactive p53 (intensity scoring 1 to 4) as assessed by monoclonal antibody PAb 1801 (P=0.02, Table IV ). In contrast, mutation of the p53 gene was strongly associated with the presence of detectable levels of immunoreactive p53 (intensity scoring I to 4) as assessed with monoclonal antibody PAb 240 (P<0.0001, Table IV ). Indeed only 4% (2/51) of point mutations of p53 were not associated with overexpression of p53 protein as detected by monoclonal antibody PAb 240. In contrast 27% (14/51) of mutations did not give rise to detectable levels of p53 overexpression as assessed with monoclonal antibody PAb 1801.
Patient survival was analysed in light of these lesions. Kaplan-Meier plots were contructed with patients stratified according to either PAb 1801 status (Figure 3) , whereby all tumours that showed any degree of staining were considered positive for p53 overexpression or PAb 240 status (Figure 4) , whereby all tumours that showed any degree of staining were considered positive for p53 overexpression and mutation status ( Figure 5 ). All plots were analysed by log-rank analysis (Table V) . The overexpression of p53 as detected by monoclonal antibodies PAb 1801 or PAb 240 was not found to be associated with a poorer patient prognosis (P = 0.60 and P=0.72 respectively, log-rank analysis). In contrast, and in agreement with our earlier report and with others (Hamelin et ,al., 1994) , mutation of p53 was significantly associated with a poorer patient prognosis (P =0.03, log-rank analysis). Further analysis of p53 overexpression status with regards to the intensity of staining also failed to detect any significant association with prognosis.
Discussion
In this report we have shown that mutation of the p53 gene is associated with a poorer patient prognosis, whereas the presence of detectable levels of immunoreactive p53 is not. In this paper we have also shown that point mutation of the p53 gene is significantly associated with overexpression of the (Hamelin et al., 1994) . In a study on 33 lung cancer cell 0.8 -l
-------lines, Bodner et al. (1994) proposed that carcinomas with mutations of the p53 gene could be divided into two classes, (Gronostajski et al., 1984; Wynford-Thomas, 1992) , complexing with viral proteins or amplification of the mdm2 gene (Vogelstein and Kinzler, 1992) . in. However, increasingly it is being shown that the Perhaps the question that most urgently needs to be lonship between mutation of the p53 gene and overaddressed is that of the biological function of the p53 protein ssion of the protein is not a direct or absolute one. In within the neoplastic cell. Two questions in particular need to study we found concordances of 61% and 71% for be addressed. Firstly, does the presence of a point mutation )clonal antibodies PAb 1801 and PAb 240 respectively implicitly mean a non-functional protein and secondly, is the le IV), figures in close agreement with those of Dix et al.
presence of p53 protein overexpression in the absence of a lb) on a similarly sized cohort of colorectal adenocarcipoint mutation indicative of a functional or a non-functional is who found a concordance of 69% with monoclonal protein. The partial answer to the first question is that iody D07. In both studies some 10% of tumours extensive experimental work has indicated that the majority )nstrated the presence of mutations that were not of point-mutated p53 molecules have lost the ability to -iated with immunohistochemical overexpression of the suppress tumorigenesis (Levine et al., 1994) . However in (Dix et al., 1994b: 11%;  , 1993 Bell et al.. 1993; Bosari et al., 1994; Dix et al., 1994a; Nathanson et al., 1994; Mulder et al., 1995) . Direct comparisons are difficult owing to the use of many different monoclonal and polyclonal antibodies, the use of fresh tissue samples and paraffin blocks, and a general lack of consensus as to the number of cells that need to be stained for a tumour to be considered positive for p53 overexpression. Although two studies (Sun et al.. 1992 : Bosari et al., 1994 have shown relatively convincing relationships between the detection of cytoplasmic p53. this has not been found by other authors (Mulder et al., 1995) . It may be of significance that both of these studies were relatively large cohorts of paraffin-preserved samples. Until these factors are effectively analysed, the importance of p53 protein overexpression as a prognostic indicator will remain uncertain.
In contrast to Dix et al. (1994a) , but in agreement with our earlier report The mechanism by which mutation of the p53 gene is associated with a poorer patient prognosis is as yet unclear. Mutated p53 proteins are oncogenic. capable of co-operating with activated ras to fully transform primary rat fibroblasts (Eliyahu et al., 1989 : Parada et al.. 1984 : Hinds et al., 1990 . Whether this effect only happens when the mutated p53 is present in large excess of the endogeneous p53. or whether mutant p53 is able to inactivate wild-type p53 by the so called dominant negative mechanism whereby the mutant protein introduces conformational changes in the wild-type protein (Milner and Medcalf, 1991) , remains unclear.
Furthermore, evidence that shows that mutated p53 may envince 'gain of functions' not normally found in wild-type p53 makes the situation particularly complex (Dittmer et al.. 1993) . It is clear however, both in this cohort and others (Hamelin et al.. 1994 that p53 point mutation can provide prognostic information. and that p53 immunohistochemistry to detect immunoreactive p53. although easily introduced into a clinical setting. is not an acceptable surrogate for the more complex and technically demanding direct detection of p53 gene mutations.
